BioCentury
ARTICLE | Company News

Patients, payers await pricing plans for bluebird's first approved gene therapy

June 3, 2019 8:40 PM UTC

bluebird gained the first European approval of Zynteglo, a β-thalassemia gene therapy Monday, but payers and patients will have to wait until the end of next week for the company to announce pricing and commercialization plans.

bluebird bio Inc. (NASDAQ:BLUE) has previously said it is pursuing an outcomes-based annuity scheme based on an estimate that Zynteglo provides $2.1 million in lifetime value. In May, the company proposed a shared risk model with payment only if the treatment continues to work. Payments under that model would be spread over up to five yearly payments of 20%, meaning bluebird would initially shoulder 80% of the financial risk. ...

BCIQ Company Profiles

bluebird bio Inc.